At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 125 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atorvastatin for Prevention of Atrial Fibrillation Recurrence Following Pulmonary Veins Isolation: A Double-Blind, Placebo-Controlled, Randomized Pilot Trial
In Brief
A Phase 4 clinical trial evaluating Atorvastatin and Placebo for Atrial Fibrillation and 3 related conditions. Completed, enrolled 125 participants across 1 site.
Detailed Summary
To investigate whether statin therapy utilizing the drug Lipitor (atorvastatin) might be effective in preventing short-and long-term atrial fibrillation (AF) following a left atrial ablation procedure. We further hypothesize this reduction will result from diminished peri-procedural inflammation, which will be reflected in lower C-Reactive Protein (CRP) values in the blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionDec 2011
TodayJul 2026
First PostedDec 21, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.5 years ago
Interventions
Atorvastatindrug
80 mg tablet taken by mouth daily for 90 days
Placebodrug
Placebo tablet taken by mouth once daily for 90 days